Telomir Pharmaceuticals, Inc. Common Stock
TELO · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.12 | -0.01 | 0.44 | 0.21 |
| FCF Yield | -2.15% | -1.86% | -0.90% | -0.50% |
| EV / EBITDA | -32.57 | -7.27 | -43.96 | -41.59 |
| Quality | ||||
| ROIC | -16.43% | -882.25% | 3,232.83% | -394.51% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.84 | 0.14 | 0.40 | 0.21 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | -33.14% | 19.31% | -42.48% | 39.56% |
| Safety | ||||
| Net Debt / EBITDA | 6.67 | 0.13 | 0.14 | 0.40 |
| Interest Coverage | -419.95 | -3,777.88 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |